Home Featured Page 206

Featured

Latest

Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing

Weekly Psychedelic Policy Briefing: October 12, 2026

Psychedelic Bulletin: Tracking LSD Patents; Psilocybin Effective for a Year in...

PT294 – Andrew Tatarsky, Ph.D. & Juliana Mulligan – Vital Psychedelic...

Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access...

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S....

Trauma and Vulnerability to Suggestion: Redefining How We Understand Consent

COMPASS Pathways plc to announce fourth quarter and full year 2021...

Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through...

Awakn Files Patent For A New Class Of Entactogen-Like Molecules

Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study

PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

EDITOR PICKS

Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In...

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try...

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.